Skip to main content
CSL Behring Scientist)

R&D Immunology


Our world-leading immunoglobulin (Ig) franchise is the cornerstone of the Immunology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a range of serious immunologic and neurologic diseases, including Primary and Secondary Immunodeficiencies (PID and SID) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). We are optimising patient experience and convenience through more flexible ways to dose and administer our existing intravenous and subcutaneous plasma derived products.

Woman with microscope

Other efforts are exploring the potential role of IG in treating systemic inflammatory syndromes. CSL also continues its commitment to innovate for patients with Hereditary Angioedema (HAE) and we have initiated a Phase III clinical program to provide long-acting prophylaxis via an anti-Factor XIIa monoclonal antibody, CSL312. 

On this strong base of product and disease expertise, CSL is leveraging its immunology expertise into programs in several new diseases and mechanistic pathways. We are embarking on Phase II/III programs in Dermatomyositis (DM) and Systemic Sclerosis (SSc), two major areas of unmet need. Meanwhile, CSL324, CSL’s anti-GCSF receptor monoclonal antibody is being trialled in inflammatory skin disease, and early plans are in place for further studies in other neutrophil-mediated inflammatory conditions. We are also continuing to explore the therapeutic potential of CSL730, a novel recombinant trivalent human IgG1 Fc multimer for the treatment of patients with immune complex-mediated autoimmune diseases such Myasthenia Gravis (MG) and Lupus Nephritis (LN). CSL Behring is committed to building on our deep knowledge and expertise in chronic and serious immunologic and neurologic diseases with the goal of saving lives and addressing the unmet need of patients worldwide.